stockguard Tuesday, 12/29/20 12:46:24 PM Re: None Post # of 2570 ATNM H.C. Wainwright keeps Buy on Actinium amid 'headline disappointment' H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating on Actinium Pharmaceuticals with a $65 price target after the independent Data Monitoring Committee recommended that the SIERRA trial continue as planned to full enrollment of 150 patients. The analyst attributes today's stock selloff to "headline disappointment" that the study was not halted for efficacy, despite the "strong" clinical efficacy and safety profile of Iomab-B to date. However, it is important to highlight that for this relatively small study targeting 150 patients in total, the statistical hurdle was quite high for this Data Monitoring Committee look, Pantginis tells investors in a re search note. The final p-value required for success still remains 0.046, adds the analyst. Pantginis continues to project a positive outcome for SIERRA and believes that the readout could come in mid-2021. SIERRA could deliver "game-changing therapy" for active relapsed or refractory acute myeloid leukemia, says Pantginis. 10:29 EST ATNM Actinium selloff today 'clear buying opportunity,' says JonesTrading JonesTrading analyst Soumit Roy reiterates a Buy rating on Actinium Pharmaceuticals with a $40 price target after the company announced that the Data Monitoring Committee recommended for the continuation of the Phase 3 SIERRA trial in active relapsed or refractory acute myeloid leukemia to completion. Actinium did not receive the unblinded primary and secondary endpoint efficacy data from SIERRA, Roy tells investors in a research note. Regarding today's stock weakness, the analyst says that given the "robust" efficacy data from SIERRA at 75% completion, there was expectations among investors that SIERRA could get terminated earlier before full completion. However , Roy points out that the Data Monitoring Committee's decision was based on less than two-thirds of the total trial size, so the trigger for early stoppage was higher than the two-times threshold for six month disease control rate at 100% enrollment. Most of the pressure on the stock today is due to selloff from retail investors and is a "clear buying opportunity," Roy says. Actinium shares in morning trading is down 25% to $8.04.